ContraFect Corp
Company Profile
Business description
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Contact
28 Wells Avenue
3rd Floor
YonkersNY10701
USAT: +1 914 207-2300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
23
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,057.60 | 48.70 | -0.53% |
CAC 40 | 7,830.16 | 41.86 | -0.53% |
DAX 40 | 23,679.16 | 67.83 | 0.29% |
Dow JONES (US) | 46,437.07 | 144.29 | 0.31% |
FTSE 100 | 9,249.51 | 26.19 | 0.28% |
HKSE | 26,518.65 | 359.53 | 1.37% |
NASDAQ | 22,594.85 | 21.38 | 0.09% |
Nikkei 225 | 45,630.31 | 136.65 | 0.30% |
NZX 50 Index | 13,181.31 | 44.77 | 0.34% |
S&P 500 | 6,666.28 | 9.36 | 0.14% |
S&P/ASX 200 | 8,764.50 | 50.50 | -0.57% |
SSE Composite Index | 3,853.64 | 31.81 | 0.83% |